Advantage Alpha Capital Partners LP Sells 12,146 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Advantage Alpha Capital Partners LP reduced its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 48.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,050 shares of the biopharmaceutical company's stock after selling 12,146 shares during the quarter. Advantage Alpha Capital Partners LP's holdings in Catalyst Pharmaceuticals were worth $272,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $27,000. Farther Finance Advisors LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after buying an additional 1,495 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 2,994 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $65,000. Finally, KBC Group NV grew its stake in Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after acquiring an additional 1,542 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Remove Ads

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares of the company's stock, valued at $4,333,200.72. This represents a 25.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Trading Down 0.1 %

Shares of NASDAQ:CPRX traded down $0.02 on Tuesday, reaching $25.72. 1,742,618 shares of the company traded hands, compared to its average volume of 1,063,301. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $26.16. The business's 50-day simple moving average is $22.53 and its 200 day simple moving average is $21.72. The stock has a market capitalization of $3.12 billion, a P/E ratio of 21.80, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on CPRX shares. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Stephens reaffirmed an "overweight" rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Finally, Bank of America restated a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $32.29.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.